Application of the enzymatic method for the quantitative determination of dequalinium chloride in lozenges

Abstract

Aim. To develop a new kinetic spectrophotometric enzymatic method suitable for the quantitative determination of dequalinium chloride in lozenges.

Materials and methods. An enzymatic kinetic spectrophotometric method for the quantitative determination of dequalinium chloride in lozenges has been proposed. It is based on the ability of dequalinium chloride to inhibit the enzymatic hydrolysis reaction of acetylcholine by cholinesterase in the presence of the acetylcholine (ACh) excess and H$_2$O$_2$. The degree of inhibition was determined by the kinetic method using two conjugated reactions: ACh perhydrolysis (interaction with an excess of hydrogen peroxide) followed by oxidation with the peroxyacid formed. Peracetic acid formed in situ by the reaction between unreacted ACh and H$_2$O$_2$ interacts with p-phenetidine forming a product, which absorbs at $\lambda_{\text{max}} = 358$ nm, in the phosphate buffer solution with pH 8.3 at room temperature.

Results and discussion. The linear dependence of the calibration graph for the quantitative determination of dequalinium chloride was in the concentration range of 0.2 – 0.8 μg mL$^{-1}$ ($r = 0.999$). LOD and LOQ were 0.01 × 10$^{-6}$ and 0.03 × 10$^{-6}$ mol L$^{-1}$, respectively. For the quantitative determination of dequalinium chloride in lozenges, RSD ≤ 2.65 % (accuracy, $\delta = -1.10\ldots+1.78$ %).

Conclusions. A new enzymatic kinetic spectrophotometric method has been developed, and its applicability to the quantitative determination of dequalinium chloride in lozenges has been shown. It does not require a complicated treatment of the analyte and a tedious extraction procedure. The method proposed is sensitive enough to determine a small amount of the active pharmaceutical ingredient. These advantages encourage the application of the method proposed in routine quality control of the drugs studied in analytical laboratories.

Keywords: dequalinium chloride; cholinesterase; acetylcholine; quantification
Introduction

For more than 60 years dequalinium chloride (DQ) has been used as an anti-infective drug, mainly to treat local infections. Nowadays, it is a common ingredient of sore-throat lozenges. As a lipophilic bis-quaternary ammonium salt (Figure 1) the drug exhibits membrane effects and selectively targets mitochondria to deplete DNA and block energy production in cells. Beyond its mitochondriotropic property, DQ can interfere with the correct functioning of diverse proteins. A dozen of DQ protein targets have been identified; their implication for the antibacterial, antiviral, antifungal, antiparasitic, and anticancer properties of the drug has been discussed [1]. The clinical efficacy and potential attractiveness of this substance have been confirmed by numerous publications [2–5]. Today, the Ukrainian pharmaceutical industry produces a number of local antiseptics with DQ, which are used to treat diseases of the upper respiratory tract. Thus, the question of choosing the method of analysis for lozenges with DQ is relevant.

To quantify DQ, the European Pharmacopoeia proposes the method of non-aqueous titration. Acetic anhydride and formic acid are used as solvents, 0.1 M perchloric acid solution is applied as a titrant, and the end point of the titration is recorded potentiometrically [6]. The British Pharmacopoeia also recommends non-aqueous titration to quantify DQ with the perchloric acid solution in a mixture of dioxane/glacial acetic acid with addition of mercury(II) acetate, and crystalline violet is used as an indicator [7]. Additionally, the method of high-performance liquid chromatography is also widely used in the analysis of DQ [8–11]. Several works proposed the method of spectrophotometry for the quantitative determination of DQ [12–14]. All the methods mentioned above have certain advantages; however, they require specific equipment and trained staff.

Thereby, the aim of the current study was to develop a simple, fast, sensitive and affordable method for the quantitative analysis of DQ, particularly in lozenges for treating throat diseases. Previously, we developed a simple, fast, sensitive kinetic-enzymatic spectrophotometric method for the determination of another quaternary ammonium salt – benzalkonium chloride in various dosage forms [15].

Materials and methods

Reagents and equipment

Dequalinium chloride (pp. 1410001632, OLON, Italy) with the active substance content of 94.8% was used in the work.

Figure 1. The structure of dequalinium chloride

INN: Dequalinium dichloride
Chemical name: 1,1’-(decane-1,10-diyl)bis(4-amino-2-methylquinolin-1-ium)
Molecular weight: 527.6

Copyright© 2022, M. Ye. Blazheyevskiy, O. V. Koval’ska. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0).
p-Phenetidine, 98% (Sigma-Aldrich); p-Phenetidine hydrochloride was prepared by dissolution of p-phenetidine in chloroform followed by precipitation of the salt by gaseous HCl.

Acetylcholine chloride, 0.2 g of the substance in ampoules, was of pharmaceutical grade (the State Science Center of Virology and Biotechnology “Vector”, Russia).

Disodium hydrogen phosphate dodecahydrate (Na₂HPO₄·12H₂O), puriss. p.a. (“ReaChem”, Kharkiv, Ukraine), and a dry cholinesterase from horse serum (SMU “Biomed”, Russia), 80 mg (VI class, activity 22 AU mg⁻¹), were used in the study. The catalytic activity of 1 activity unit (AU) is manifested by such an amount of this enzyme preparation that converts 1 µmol of the substrate in 1 min under given reaction conditions.

Stabilized hydrogen peroxide, 30–40% solution, puriss. p.a. (LLC Inter-Synthes, Boryslav, Ukraine) was used; the precise content of hydrogen peroxide was determined by permanganometry according to the State Pharmacopeia of Ukraine [16].

High purity double-distilled water was used during our experiments.

“Amilar IC” – orange-flavored lozenges. Active ingredients (in 1 tablet) are: dequalinium chloride, 0.25 mg, dibucaine hydrochloride, 0.03 mg, manufactured by “InterChem SLC” (Ukraine), batch number s.02501118.

“Dekvadol” – white tablets. Active ingredients (in 1 tablet) are: dequalinium chloride, 0.25 mg, dibucaine hydrochloride, 0.03 mg, manufactured by JSC “Kyiv Vitamin Plant” (Ukraine), batch number VM 491219.

“Lizak” – grey to brown tablets. Active ingredients (in 1 tablet) are: dequalinium chloride, 0.25 mg, lysozyme hydrochloride, 10 mg, manufactured by JSC “Farmak”, Ukraine, batch number s. 150920.

The absorbance measurements were performed on a colorimeter (CFC-2) (Zagorsky optical and mechanical plant, Russia) using quartz cells with a width of 1 cm.

The pH measurements were performed with a combined glass electrode (SP20B) together with an EAL-1M3.1 reference standard silver chloride electrode.

Preparation of 0.2 M phosphate buffer solution (pH 8.3)
Disodium hydrogen phosphate dodecahydrate (35.75 g) was dissolved in 500 mL of double-distilled water, and a 0.1 M solution of hydrochloric acid (19 mL) was then added. The pH of the final solution was controlled by potentiometry.

Preparation of 10% hydrogen peroxide solution
The solution was prepared by dilution of hydrogen peroxide (30–40%) with the required amount of double distilled water. The content of hydrogen peroxide in 10% working solution was determined by permanganometry.

Preparation of 1% p-phenetidine hydrochloride solution
1.00 g of p-phenetidine hydrochloride was dissolved in 80 mL of double-distilled water in a 100 mL volumetric flask and diluted to the volume with the same solvent.

Preparation of cholinesterase (ChE) solution
In a flask containing a dry powder of cholinesterase (80 mg) double-distilled water (10 mL) was added, and the flask was moved to a thermostat for 10 min at a temperature of 37–40°C.

Preparation of acetylcholine chloride (ACH) solution
The ampoule content (0.2 g of ACh) was dissolved in 200 mL of double-distilled water. For this purpose, an ampoule was opened, 4.0 mL of water was pipetted and added to the ampoule and then shaken until ACh was completely dissolved. Then the ACh solution was transferred into a 200 mL volumetric flask and diluted to the volume with double-distilled water [17].

Preparation of the stock solution
0.05277 g (accurate weight) of the DQ substance (the active substance content w = 94.8%) was dissolved in double-distilled water in a 100.0 mL volumetric flask, and the solution was diluted to the volume with the same solvent (with the concentration of 0.5 mg mL⁻¹) at 20°C. The content of the flask was mixed thoroughly.

10.00 mL of the initial solution was pipetted into a 100.0 mL volumetric flask, and the solution was diluted to the volume with double-distilled water at 20°C. The content of the flask was mixed thoroughly (with the concentration of 50 µg mL⁻¹).

The general procedure for the quantitative determination
The first part: 10.0 mL of 0.2 M phosphate buffer solution (pH = 8.3) was transferred into a 20 mL graduated test tube with a ground stopper, 1% ACh solution (1.0 mL) and 10% hydrogen peroxide solution (2.0 mL) were consecutively added, and the stopwatch was started. After that, the solution was shaken thoroughly and thermostated for 10 min at a temperature of 37°C. Then 1% p-phenetidine hydrochloride solution (1.0 mL) was added to the test tube, and
the solution was diluted to the volume with double-distilled water. The stopwatch was started again, and the solution was scanned photometrically every minute over the period of 15 min on a photoelectric colorimeter, the color filter No.2 ($\lambda_{\text{max}} = 358$ nm) and a 1.0 cm cuvette were used. The solution containing only 0.2 M phosphate buffer (10.0 mL, pH = 8.3) was used as a reference solution. The relative rate of the reaction $[\text{ACh} + \text{H}_2\text{O}_2] + p\text{-Ph}]$ ($tg_{\alpha_{\text{max}}}, \text{min}^{-1}$) was determined as a slope of the optical density ($A$) vs time ($t$, min) kinetic curve.

The second part: 0.2 M phosphate buffer solution (10.0 mL, pH = 8.3), 1% ACh solution (1.0 mL) and the ChE solution (2.0 mL) were transferred into a 20 mL graduated test tube with a ground stopper. After that, the solution was shaken thoroughly and thermostated for 10 min at a temperature of 37°C. Then 10% hydrogen peroxide solution (2.0 mL) was introduced into the test tube while stirring. The mixture was shaken thoroughly and kept for 10 min in a thermostat at the same temperature. Then 1% $p$-phenetidine hydrochloride solution (1.0 mL) was added, and the solution was diluted to the volume with double-distilled water. The stopwatch was started, and every minute the solution was scanned photometrically over the period of 15 min on a photoelectric colorimeter; the color filter No. 2 ($\lambda_{\text{max}} = 358$ nm) and a 1.0 cm cuvette were used. The solution containing only 0.2 M phosphate buffer (10.0 mL, pH = 8.3) was used as a reference solution. The relative rate of the reaction $[\text{ChE} + \text{DQ} + \text{ACh}] + \text{H}_2\text{O}_2 + p\text{-Ph}]$ ($tg_{\alpha_{\text{max}}}, \text{min}^{-1}$) was determined as a slope of the optical density ($A$) vs time ($t$, min) kinetic curve.

The third part: 0.2 M phosphate buffer solution (10.0 mL, pH = 8.3) was transferred into a 20 mL graduated test tube with a ground stopper. The accurate volumes of the working standard solutions of DQ or test solutions of the drugs (see below) were added into the test tube. The ChE solution (2.0 mL) was added while stirring, a stopwatch was started, and every solution was shaken thoroughly and thermostated at 37°C for 10 min. Then 1% acetylcholine solution (1.0 mL) was quickly added to the test tube, the stopwatch was started, and the mixture was shaken thoroughly and thermostated for 10 min again. After that, 10% hydrogen peroxide solution (2.0 mL) was added, the mixture was kept in the thermostat for 10 min; further 1% $p$-phenetidine hydrochloride solution (1.0 mL) was added, and the solution was diluted to the volume with double-distilled water. The stopwatch was started, and the solution was scanned photometrically on a photoelectric colorimeter every minute over a period of 15 min; the color filter No. 2 ($\lambda_{\text{max}} = 358$ nm) and a 1.0 cm cuvette were used. The solution containing 0.2 M phosphate buffer (10.0 mL, pH = 8.3) was used as a reference solution. The relative rate of the reaction $[(\text{ChE} + \text{DQ}) + \text{ACh}] + \text{H}_2\text{O}_2 + p\text{-Ph}]$ ($tg_{\alpha_{\text{max}}}, \text{min}^{-1}$) was determined as a slope of the optical density ($A$) vs time ($t$, min) kinetic curve.

The calibration graph procedure

Working standard solutions 1-7 used for calibration

4.00, 6.00, 8.00, 10.00, 12.00, 14.00, 16.00 mL of the stock solution were pipetted into a series of 50.0 mL volumetric flasks, and the solutions were diluted to the volume with double-distilled water at 20°C (final concentrations were 4.0; 6.0; 8.0; 10.0; 12.0; 14.0; 16.0 μg mL$^{-1}$, respectively).

The performance of the method proposed was verified on the sample concentrations of 0.2; 0.3; 0.4; 0.5; 0.6; 0.7; 0.8 μg mL$^{-1}$ according to the General procedure.

The inhibition degree of the enzymatic hydrolysis of acetylcholine ($U$, %), in the presence of DQ was calculated by the following formula:

$$U(\%) = \frac{tg_{\alpha_{\text{max}}} - tg_{\alpha_{\text{min}}}}{tg_{\alpha_{\text{max}}} - tg_{\alpha_{\text{min}}}} \times 100 \%$$

where $tg_{\alpha_{\text{max}}}, \text{min}^{-1}$ – is the relative rate of the $p$-phenetidine oxidation reaction with peroxyacetic acid formed in the reaction of ACh perhydrolysis (in the absence of ChE and DQ); $tg_{\alpha_{\text{min}}}, \text{min}^{-1}$ – is the relative rate of the $p$-phenetidine oxidation reaction with peroxyacetic acid formed in the reaction of perhydrolysis of unreacted ACh (in the presence of ChE and in the absence of DQ); $tg_{\alpha_{\text{min}}}, \text{min}^{-1}$ – is the relative rate of the $p$-phenetidine oxidation reaction with peroxyacetic acid formed in the reaction of perhydrolysis of unreacted ACh (in the presence of ChE and DQ with the concentration $c_i$).

Results and discussion

Parameters that can affect the performance of the method proposed were studied to reach the optimum working conditions and reagent concentrations [18].

The measurement velocity of changing the absorption vs time ($\Delta A/\Delta t$, min$^{-1}$) made it possible
to quantify DQ in the substance. Figure 2 shows the kinetic curves of the reaction of \( p \)-phenetidine oxidation by hydrogen peroxide in the presence of different concentrations of DQ. They have a linear character at the initial stage; it allows us to use the slope \((\tan \alpha)\) of kinetic lines as the value of an analytic signal that corresponds to a certain content DQ in the sample.

The range of application of this procedure was 0.2 – 0.8 mg mL\(^{-1}\). The calibration graph (Figure 3) was constructed in the coordinates of the concentration (mol L\(^{-1}\)) vs the inhibition degree (%).

According to the data obtained on the inhibition degree of ChE by various concentrations of DQ, the calibration dependence was constructed in absolute and normalized coordinates (normalization was performed according to the nominal content in the drug): \( U = b_1X + a_1 \) and \( Y = b_2X + a_2 \), respectively (Tables 1 and 2). The least squares method was used to calculate the metrological characteristics of the calibration dependences obtained (angular coefficient \( b \) and its standard deviation \( S_b \), free term \( a \), and its standard deviation \( S_a \), as well as correlation coefficient (R) and residual standard deviation RSD\(_0\) (Table 1).

**Table 1.** Metrological characteristics of the linear dependence of the inhibition degree of the enzymatic hydrolysis of acetylcholine \((U, \%)\) on the concentration of the dequalinium chloride solution

| Linearity parameters | \( U = b_1X + a_1 \) | \( Y = b_2X + a_2 \) |
|----------------------|-------------------|-------------------|
| \( b \)              | 97.1 \times 10^6  | 1.45              |
| \( S_b \)            | 0.9 \times 10^6   | 0.01              |
| \( a \)              | -14.1             | -0.42             |
| \( S_a \)            | ±0.5              | 1.50              |
| \( R \)              | 0.99997           | 0.9997            |
| RSD\(_0\)            | 0.49              | 1.47%             |
| LOD                  | 0.01 \times 10^{-6} mol L\(^{-1}\) | – |
| LOQ                  | 0.03 \times 10^{-6} mol L\(^{-1}\) | – |

**Figure 2.** Kinetic curves of \( p \)-phenetidine oxidation by hydrogen peroxide in the presence of the system: 1 – ACh + ChE, 2 – 8 –ACh + (ChE + DQ), 9 – ACh; \( w(\text{ACh}) = 1\%; \text{ChE} = 22 \text{AU}; c(DQ), \mu g \text{mL}^{-1}: 2 – 0.2, 3 – 0.3, 4 – 0.4, 5 – 0.5, 6 – 0.6, 7 – 0.7, 8 – 0.8

**Figure 3.** The calibration graph of the dependence of the inhibition degree of the enzymatic hydrolysis of acetylcholine \((U, \%)\) on the concentration of the dequalinium chloride solution.
From Table 1 one can conclude that the parameters of the calibration linear dependence constructed in normalized coordinates are characterized by satisfactory linearity for the given range of concentrations.

The recommended procedure for the analysis of “Amilar IC”, “Dekvadol” and “Lizak” drugs

Twenty (20) tablets of each “Amilar IC”, “Dekvadol” and “Lizak” drugs were crushed to homogeneity, and 2.5097 g (accurate weight) of this powder was dissolved in double-distilled water in a 100 mL volumetric flask. The solution was filtered, the filter was washed, and diluted to the volume with double-distilled water. The analysis was performed according to the General procedure.

The quantitative content (x) of dequalinium chloride (C30H40Cl2N2) in one tablet (lozenges) was calculated by the following equation:

\[
x (g) = \frac{m_{st} \times w \% \times U_{sample} \times 100 \times 20 \times m_{tabl}}{m_{x} \times U_{st} \times 100 \%}
\]

where \(m_{st}\) – is the mass of the standard sample of the DQ substance, 0.05277 g;

\(w\) – is the active substance content in the working standard solutions of DQ, %;

\(U_{sample}\) – is the cholinesterase inhibition degree by the working sample, %;

\(U_{st}\) – is the cholinesterase inhibition degree by the standard sample, %;

\(m_{tabl}\) – is the average mass of the drug working samples, g;

100, 10, 20 – is dilution coefficients.

The degree of inhibition (\(U_{sample}\) and \(U_{st}\) in %) was calculated according to the procedure described in the literature [19].

The data obtained and presented in Table 3 indicate the possibility to use the method proposed for the quantitative determination of DQ in lozenges.

### Table 2. The results of the analysis of the working standard solutions and their statistical processing

| \(C_{x}\), mg mL\(^{-1}\) | \(x_{i}\), % | Degree of inhibition ChE | Found (%) to \(U_{reference}\) \(Y_{p}\) % | The calculated concentration of DQ in the solutions \(X_{calc}\), % | \(RR_{i}\), % = \(X_{calc}^i \times 100\% / X_{i}\) |
|-----------------|--------|-------------------|-------------------|-------------------|--------------------------|
| 0.2             | 40     | 5.02              | 14.99             | 39.31             | 98.26                    |
| 0.3             | 60     | 15.32             | 45.73             | 60.51             | 100.85                   |
| 0.4             | 80     | 24.15             | 72.09             | 78.69             | 98.36                    |
| 0.5             | 100    | 33.95             | 101.34            | 98.87             | 98.87                    |
| 0.6             | 120    | 45.21             | 134.96            | 122.05            | 101.71                   |
| 0.7             | 140    | 52.65             | 157.16            | 137.37            | 98.12                    |
| 0.8             | 160    | 62.54             | 186.69            | 157.73            | 98.58                    |

\(RR_{i}\), % = \(|100 – RR|\)
\(\delta_{i} \% = |\delta_{i}/\mu| \times 100\% \times \mu^{-1}\) satisfied
\(RSD_{max} \% = 1.43\)
\(\Delta_{cal} \% = RSD_{max} \times t(95\%, n – 1)\)
\(\Delta_{cal} \% \leq max\Delta_{x} = 3.05\%\) satisfied

### Table 3. The results of the quantitative determination of DQ in lozenges by the method proposed

| Drug    | Manufacturer, pharmaceutical factory | The content of DQ (mg) | DQ Found, \((\bar{X} \pm \Delta X), mg\)\[a]\ | RSD, % | Accuracy (\(\delta, \%\))\[b] |
|---------|-------------------------------------|-----------------------|-----------------------------------------------|--------|-----------------------------|
| Amilar IC | Ukraine, ALC “Interhem” s. 02501118 | 0.2422               | 0.246 \pm 0.0081                               | 2.65   | +1.56                       |
| Dekvadol | Ukraine, PC “Kyiv Vitamin Plant”, VM 491219 | 0.2513               | 0.2518 \pm 0.0030                             | 1.17   | -1.10                       |
| Lizak   | Ukraine, PC “Farmak” s. 150920       | 0.258                | 0.2534 \pm 0.0058                             | 1.86   | +1.78                       |

Notes: \[a\] Mean of 5 measurements (P = 0.95); \[b\] \(\delta = (\bar{X} – \mu) \times 100\% \times \mu^{-1}; \mu is the actual content of DQ according to the Certificate
References

1. Bailly, C. Medicinal applications and molecular targets of dequalinium chloride. *Biochem Pharmacol* 2021, 186, 114467. https://doi.org/10.1016/j.bcp.2021.114467.

2. Abaturov, O. Y.; Ahafonova, O. O.; Tokarieva, N. M. Application of lysozyme and dequalinium chloride in the treatment of acute respiratory diseases of the upper respiratory tract in children. *CHILD’S HEALTH* 2021, 13 (6), 576–584. https://doi.org/10.22141/2224-0551.13.6.2018.143163.

3. Tekgunduz, S. E.; Saracoglu, F. Evaluation of the Effectiveness of Dequalinium Chloride Vaginal Tablets in Aerobic Vaginitis: A Placebo-Controlled Study. *Eastern Journal of Medical Sciences* 2021, 6 (3), 50–56. https://doi.org/10.32677/ejms.v6i3.3090.

4. Pan, Y.; Zhao, S.; Chen, F. The potential value of dequalinium chloride in the treatment of cancer: Focus on malignant glioma. *Clinical and Experimental Pharmacology and Physiology* 2021, 48 (4), 445–454. https://doi.org/10.1111/1440-1681.13466.

5. Macé, S.; Truelstrup Hansen, L.; Rupasinghe, H. P. V. Anti-Bacterial Activity of Phenolic Compounds against Streptococcus pyogenes. *Medicines* 2017, 4 (2), 25. https://doi.org/10.3390/medicines4020025.

6. *European Pharmacopoeia*, 6th Ed.; European Directorate for the Quality of Medicines: Strasbourg, 2008.

7. *British Pharmacopoeia*; The Stationery Office: London, 2008.

8. Taylor, R. B.; Toasakişri, S.; Reid, R.; Wood, D. Determination of the Quaternary Ammonium Compounds Dequalinium and Cetylpyridinium Chlorides in Candy-based Lozenges by High-performance Liquid Chromatography. *Analyst* 1997, 122 (9), 973–976. https://doi.org/10.1039/A703893C.

9. Taylor, R. B.; Toasakişri, S.; Reid, R. G. Capillary electrophoresis and liquid chromatography in the analysis of some quaternary ammonium salts used in lozenges as antibacterial agents. *Journal of capillary electrophoresis* 1998, 5 (1–2), 45–50.

10. Chen, F.-A.; Wu, K.-S.; Huang, M.-C.; Chen, C.-Y.; Wu, A.-B. Simultaneous quantitation of cationic disinfectants by high-performance liquid chromatography on a silica gel column using aqueous eluents. *Journal of Food and Drug Analysis* 2001, 9 (4), Article 4. https://doi.org/10.38212/2224-6614.2780.

11. Fang, W.-H; Liu, J.; Shen, J.; Zhang, L.-J. Application of the kinetic enzymatic method for benzalkonium chloride determination in an aerosol preparation. *GISAP: Medical Sciences, Pharmacology* 2011, 7, 837–839.

12. Mohamed, H. A. Spectrophotometric Determination of Dequalinium Chloride. *Anal. Lett.* 1993, 26 (11), 2421–2429. https://doi.org/10.1080/00032719308017481.

13. Leung, C. P.; Kwan, S. Y. Spectrophotometric determination of dequalinium chloride in pharmaceutical preparations. *Analyst* 1979, 104 (1235), 143–146. https://doi.org/10.1039/AN7990040143.

14. Mohamed, T. Y.; Dossouki, H. A.; Moustafa, M. M.; Ghanime. M. S. Spectrophotometric methods for the determination of dequalinium chloride and clidinium bromide using ion-pair complex formation with acid dyes. *Egyptian Journal of Chemistry*, 2008, 51 (1), 113–123.

15. Blazheevskiy, M. Ye.; Koval’ska, O. V. Application of the kinetic enzymatic method for benzalkonium chloride determination in an aerosol preparation. *GISAP: Medical Sciences, Pharmacology* 2017, 13, 33–35.

16. *Derzhavna farmakopeia Ukrainy*: v 3 tomakh, 2 vydannia [The State Pharmacopoeia of Ukraine: in 3 volumes, 2nd ed., in Ukrainian]; State Enterprise “Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines”: Kharkiv, 2015; Vol. 1.

17. Diadchenko, V. V.; Petruchkin, S. Yu.; Novikov, O. I. Boiovi tokyschi khimichni rechovyny: v 3 tomakh [Fighting toxic chemicals: in 3 volumes, in Ukrainian]; Brovin O. V.; Kharkiv, 2018; Vol. 1.

18. Blazheevskiy, M. E.; Koval’ska, O. V.; Dyadchenko, V. V. (National University of Pharmacy, Kharkiv, Ukraine). Sposob vyznachennia aktyvnosti kholinesterazy krovi [Method for determining blood cholinesterase activity, in Ukrainian]. Ukraine Patent 117474, 26.06.2017.

19. Koval’ska, O. V.; Blazheevskiy M. Y. The Enzymatic Method for the Quantitative Determination of Benzalkonium Chloride in the Antiseptic Solution “CUTASEPT® F.” *Journal of Organic and Pharmaceutical Chemistry* 2021, 19 (4), 33–39. https://doi.org/10.24959/ophcj.21.244359.

Authors information:

Mykola Ye. Blazheevskiy, D.Sc. in Chemistry, Professor of the Inorganic and Physical Chemistry Department, National University of Pharmacy of the Ministry of Health of Ukraine; https://orcid.org/0000-0002-8032-347X.

Olena V. Koval’ska [corresponding author], Ph.D. in Pharmacy, Associate Professor of the Inorganic and Physical Chemistry Department, National University of Pharmacy of the Ministry of Health of Ukraine; https://orcid.org/0000-0003-0113-7060; e-mail for correspondence: lena05021985@ukr.net; tel. +380 97 0710498.